peptide-repo/peptide-repo-core
1
0
Fork 0
Code Issues Pull Requests Actions Packages Projects Releases Wiki Activity
Files
main
peptide-repo-core/includes/class-pr-core-seed-fixtures.php
peptiderepo 665d7fa9e1 Adopt reusable CI standard + PHPUnit conversion (#22) 
Squash-merge of PR #22: adopt shared reusable CI workflow, convert PHPUnit to stubs, update branch-protection contexts.

QA-approved at 05d8094a1d. All required CI checks green.

Agent-Session: 2026-06-17-prcore-ci-deploy
2026-06-17 01:12:00 +07:00

266 lines
9.0 KiB
PHP
Raw Permalink Blame History

<?php
/**
* Seed Fixtures.
*
* @package Peptide_Repo_Core
*/
declare(strict_types=1);
/**
* Provides hard-coded peptide, dosing, and legal data used by PR_Core_Seed_Data
*
* @package Peptide_Repo_Core
*/
/**
* Static seed data fixtures for development and testing.
*
* What: Provides hard-coded peptide, dosing, and legal data used by PR_Core_Seed_Data.
* Who calls it: PR_Core_Seed_Data — calls get_peptides(), get_dosing_rows(), get_legal_cells().
* Dependencies: None.
*
* @see class-pr-core-seed-data.php — Orchestrator that consumes these fixtures.
*/
class PR_Core_Seed_Fixtures {
/**
* Return the canonical list of peptide fixture definitions.
*
* @return array<int, array<string, mixed>>
*/
public static function get_peptides(): array {
return array(
array(
'title' => 'BPC-157',
'slug' => 'bpc-157',
'excerpt' => 'Body Protection Compound-157, a pentadecapeptide derived from human gastric juice.',
'display_name' => 'BPC-157',
'aliases' => '["Body Protection Compound-157","Bepecin","PL 14736","PL-10"]',
'molecular_formula' => 'C62H98N16O22',
'molecular_weight' => 1419.53,
'cas_number' => '137525-51-0',
'drugbank_id' => '',
'chembl_id' => '',
'evidence_strength' => 'observational',
),
array(
'title' => 'Semaglutide',
'slug' => 'semaglutide',
'excerpt' => 'A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.',
'display_name' => 'Semaglutide',
'aliases' => '["Ozempic","Wegovy","Rybelsus"]',
'molecular_formula' => 'C187H291N45O59',
'molecular_weight' => 4113.58,
'cas_number' => '910463-68-2',
'drugbank_id' => 'DB13928',
'chembl_id' => 'CHEMBL3137309',
'evidence_strength' => 'meta-analysis',
),
array(
'title' => 'TB-500',
'slug' => 'tb-500',
'excerpt' => 'Thymosin Beta-4 fragment, a synthetic peptide used in tissue repair research.',
'display_name' => 'TB-500',
'aliases' => '["Thymosin Beta-4","T\u03b24"]',
'molecular_formula' => 'C212H350N56O78S',
'molecular_weight' => 4963.44,
'cas_number' => '77591-33-4',
'drugbank_id' => '',
'chembl_id' => '',
'evidence_strength' => 'preclinical',
),
);
}
/**
* Return the canonical list of dosing row fixture definitions.
*
* @return array<int, array<string, mixed>>
*/
public static function get_dosing_rows(): array {
return array(
array(
'peptide' => 'bpc-157',
'dose_min' => 200,
'dose_max' => 300,
'dose_unit' => 'mcg',
'route' => 'subq',
'frequency' => 'twice daily',
'population' => 'healthy',
'evidence_strength' => 'observational',
'study_title' => 'BPC 157 in wound healing review',
'study_year' => 2021,
'citation_pubmed_id' => '34537800',
),
array(
'peptide' => 'bpc-157',
'dose_min' => 500,
'dose_max' => 500,
'dose_unit' => 'mcg',
'route' => 'subq',
'frequency' => 'daily',
'population' => 'healthy',
'evidence_strength' => 'case-series',
'study_title' => 'Subcutaneous BPC-157 in tendon repair',
'study_year' => 2019,
'citation_pubmed_id' => '30915550',
),
array(
'peptide' => 'bpc-157',
'dose_min' => 10,
'dose_max' => 10,
'dose_unit' => 'mcg',
'route' => 'oral',
'frequency' => 'daily',
'population' => 'animal',
'evidence_strength' => 'preclinical',
'study_title' => 'Oral BPC-157 in rat gastric ulcer model',
'study_year' => 2018,
'citation_pubmed_id' => '29869189',
),
array(
'peptide' => 'bpc-157',
'dose_min' => 250,
'dose_max' => 750,
'dose_unit' => 'mcg',
'route' => 'im',
'frequency' => 'daily',
'population' => 'clinical',
'evidence_strength' => 'case-series',
'study_title' => 'Intramuscular BPC-157 for muscle injuries',
'study_year' => 2020,
'citation_pubmed_id' => '33312000',
),
array(
'peptide' => 'semaglutide',
'dose_min' => 0.25,
'dose_max' => 0.25,
'dose_unit' => 'mg',
'route' => 'subq',
'frequency' => 'weekly',
'population' => 'clinical',
'evidence_strength' => 'rct-large',
'study_title' => 'SUSTAIN 1: Semaglutide in T2DM',
'study_year' => 2017,
'citation_pubmed_id' => '28930514',
'indication' => 'Type 2 diabetes initiation dose',
),
array(
'peptide' => 'semaglutide',
'dose_min' => 1.0,
'dose_max' => 1.0,
'dose_unit' => 'mg',
'route' => 'subq',
'frequency' => 'weekly',
'population' => 'clinical',
'evidence_strength' => 'rct-large',
'study_title' => 'SUSTAIN 6: CV outcomes with semaglutide',
'study_year' => 2016,
'citation_pubmed_id' => '27633186',
'indication' => 'Type 2 diabetes maintenance',
),
array(
'peptide' => 'semaglutide',
'dose_min' => 2.4,
'dose_max' => 2.4,
'dose_unit' => 'mg',
'route' => 'subq',
'frequency' => 'weekly',
'population' => 'clinical',
'evidence_strength' => 'rct-large',
'study_title' => 'STEP 1: Semaglutide 2.4mg for obesity',
'study_year' => 2021,
'citation_pubmed_id' => '33567185',
'indication' => 'Chronic weight management',
),
array(
'peptide' => 'semaglutide',
'dose_min' => 14,
'dose_max' => 14,
'dose_unit' => 'mg',
'route' => 'oral',
'frequency' => 'daily',
'population' => 'clinical',
'evidence_strength' => 'rct-large',
'study_title' => 'PIONEER 1: Oral semaglutide in T2DM',
'study_year' => 2019,
'citation_pubmed_id' => '30924169',
'indication' => 'Type 2 diabetes oral formulation',
),
array(
'peptide' => 'tb-500',
'dose_min' => 2,
'dose_max' => 2.5,
'dose_unit' => 'mg',
'route' => 'subq',
'frequency' => 'twice weekly',
'population' => 'animal',
'evidence_strength' => 'preclinical',
'study_title' => 'Thymosin beta-4 promotes dermal healing in rats',
'study_year' => 2007,
'citation_pubmed_id' => '17584560',
),
array(
'peptide' => 'tb-500',
'dose_min' => 5,
'dose_max' => 5,
'dose_unit' => 'mg',
'route' => 'subq',
'frequency' => 'weekly',
'population' => 'animal',
'evidence_strength' => 'preclinical',
'study_title' => 'TB4 cardiac repair in murine MI model',
'study_year' => 2012,
'citation_pubmed_id' => '22561753',
),
);
}
/**
* Return the canonical list of legal cell fixture definitions.
*
* @return array<int, array<string, mixed>>
*/
public static function get_legal_cells(): array {
return array(
array(
'peptide' => 'bpc-157',
'country_code' => 'US',
'status' => 'ruo',
'regulatory_framework' => 'Not FDA-approved; available as Research Use Only',
'notes' => 'Compounding pharmacies may dispense under FDA 503A/503B exemptions.',
),
array(
'peptide' => 'bpc-157',
'country_code' => 'GB',
'status' => 'unclear',
'regulatory_framework' => 'Not listed by MHRA',
'notes' => 'No specific scheduling; import for personal use is a grey area.',
),
array(
'peptide' => 'semaglutide',
'country_code' => 'US',
'status' => 'prescription',
'regulatory_framework' => 'FDA-approved (Ozempic, Wegovy, Rybelsus)',
'regulatory_text_url' => 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020lbl.pdf',
'notes' => 'Schedule IV not applicable; requires valid prescription.',
),
array(
'peptide' => 'semaglutide',
'country_code' => 'GB',
'status' => 'prescription',
'regulatory_framework' => 'MHRA-approved (Ozempic, Wegovy)',
'notes' => 'Available via NHS and private prescription.',
),
array(
'peptide' => 'semaglutide',
'country_code' => 'AU',
'status' => 'prescription',
'regulatory_framework' => 'TGA-approved (Ozempic)',
'notes' => 'PBS-listed for type 2 diabetes; Wegovy approval pending as of 2025.',
),
);
}
}
Reference in New Issue View Git Blame Copy Permalink